Related papers: Deep Grading based on Collective Artificial Intell…
Detection of Alzheimer's Disease (AD) from neuroimaging data such as MRI through machine learning has been a subject of intense research in recent years. Recent success of deep learning in computer vision has progressed such research…
The automatic early diagnosis of prodromal stages of Alzheimer's disease is of great relevance for patient treatment to improve quality of life. We address this problem as a multi-modal classification task. Multi-modal data provides richer…
Identification of brain regions related to the specific neurological disorders are of great importance for biomarker and diagnostic studies. In this paper, we propose an interpretable Graph Convolutional Network (GCN) framework for the…
While deep learning-based Alzheimer's disease (AD) diagnosis has recently made significant advancements, particularly in predicting the conversion of mild cognitive impairment (MCI) to AD based on MRI images, there remains a critical gap in…
Alongside neuroimaging such as MRI scans and PET, Alzheimer's disease (AD) datasets contain valuable tabular data including AD biomarkers and clinical assessments. Existing computer vision approaches struggle to utilize this additional…
Fusing structural-functional images of the brain has shown great potential to analyze the deterioration of Alzheimer's disease (AD). However, it is a big challenge to effectively fuse the correlated and complementary information from…
Early and reliable detection of Alzheimer's disease (AD) is crucial for timely clinical intervention and improved patient management. It also supports the evaluation of emerging therapeutic strategies. In this paper, we propose a Low-Rank…
Alzheimer's disease (AD), a degenerative brain condition, can benefit from early prediction to slow its progression. As the disease progresses, patients typically undergo brain atrophy. Current prediction methods for Alzheimers disease…
Accurate diagnosis of Alzheimer's Disease (AD) entails clinical evaluation of multiple cognition metrics and biomarkers. Metrics such as the Alzheimer's Disease Assessment Scale - Cognitive test (ADAS-cog) comprise multiple subscores that…
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by progressive cognitive decline and widespread epigenetic dysregulation in the brain. DNA methylation, as a stable yet dynamic epigenetic modification,…
Alzheimer's disease and Frontotemporal dementia are two major types of dementia. Their accurate diagnosis and differentiation is crucial for determining specific intervention and treatment. However, differential diagnosis of these two types…
This paper explores deterioration in Alzheimers Disease using Machine Learning. Subjects were split into two datasets based on baseline diagnosis (Cognitively Normal, Mild Cognitive Impairment), with outcome of deterioration at final visit…
Current Computer-Aided Diagnosis (CAD) methods mainly depend on medical images. The clinical information, which usually needs to be considered in practical clinical diagnosis, has not been fully employed in CAD. In this paper, we propose a…
Accurate prediction of clinical scores is critical for early detection and prognosis of Alzheimers disease (AD). While existing approaches primarily focus on forecasting the ADAS-Cog global score, they often overlook the predictive value of…
Alzheimer's disease (AD) is a major neurodegenerative condition that affects millions around the world. As one of the main biomarkers in the AD diagnosis procedure, brain amyloid positivity is typically identified by positron emission…
The accurate diagnosis of Alzheimer's disease (AD) and prognosis of mild cognitive impairment (MCI) conversion are crucial for early intervention. However, existing multimodal methods face several challenges, from the heterogeneity of input…
Alzheimer's disease (AD) progresses through distinct stages, from early mild cognitive impairment (EMCI) to late mild cognitive impairment (LMCI) and eventually to AD. Accurate identification of these stages, especially distinguishing LMCI…
Alzheimer's disease (AD) diagnosis requires integrating neuroimaging with heterogeneous clinical evidence and reasoning under established criteria, yet most multimodal models remain opaque and weakly guideline-aligned. We present…
Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions worldwide, necessitating early and accurate diagnosis for optimal patient management. In recent years, advancements in deep learning have shown remarkable potential…
Longitudinal assessment of brain atrophy, particularly in the hippocampus, is a well-studied biomarker for neurodegenerative diseases, such as Alzheimer's disease (AD). In clinical trials, estimation of brain progressive rates can be…